Audrey Gabelle
YOU?
Author Swipe
Impact of preanalytical delay on the performance of plasma Aβ42, Aβ42/40, p‐tau217, and p‐tau217/Aβ42 in detecting brain amyloidosis in the ALZAN cohort Open
BACKGROUND Alzheimer disease (AD), the leading cause of dementia, has increased interest in the development of blood‐based biomarkers for early diagnosis and monitoring. The plasma amyloid beta (Aβ)42/Aβ40 ratio and phosphorylated tau (p‐t…
Beyond amyloid and tau: synaptic and neurodegenerative biomarkers shape MCI progression Open
Summary Background Accurate prediction of which patients with mild cognitive impairment (MCI) will progress to Alzheimer’s disease (AD) remains a major unmet clinical need. Current biomarkers detect amyloid pathology with high accuracy but…
View article: Oral Blarcamesine Phase IIb/III Trial Confirms Identified Precision Medicine Patient Population – Significant Broad Clinical and Quality of Life Improvements for Early Alzheimer’s Disease Patients
Oral Blarcamesine Phase IIb/III Trial Confirms Identified Precision Medicine Patient Population – Significant Broad Clinical and Quality of Life Improvements for Early Alzheimer’s Disease Patients Open
IMPORTANCE There are no approved oral disease-modifying treatments for Alzheimer’s disease (AD) with the ability to prolong time in a stable disease state and with clinically meaningful outcomes clear to patients and caregivers. DESIGN The…
A six-year risk assessment for dementia and Alzheimer's disease in the general population through immunoprecipitation-mass spectrometry plasma amyloid quantification Open
This research advances the potential application of plasma amyloid biomarkers for assessing the risk of clinical dementia and AD in the general population within short period of time, positioning it as a valuable tool alongside existing pl…
View article: Faster decline of very prodromal dementia with Lewy bodies when amyloid positive
Faster decline of very prodromal dementia with Lewy bodies when amyloid positive Open
INTRODUCTION The cognitive and neuroimaging evolution during dementia with Lewy bodies (DLB) from the prodromal phase (Pro‐DLB; subjective cognitive impairment [SCI] to mild cognitive impairment [MCI]) according to amyloid beta (Aβ) status…
Smartwatch- and smartphone-based remote assessment of brain health and detection of mild cognitive impairment Open
Consumer-grade mobile devices are used by billions worldwide. Their ubiquity provides opportunities to robustly capture everyday cognition. 'Intuition' was a remote observational study that enrolled 23,004 US adults, collecting 24 months o…
Plasma Hepcidin as a potential informative biomarker of Alzheimer disease and vascular dementia Open
Blood Hepcidin and NfL have limited interest in the clinical context of AD but determination of these biomarkers shows to be highly informative for the diagnosis of VaD. This result could have important implications for diagnosis and imple…
Usefulness of Cerebrospinal Fluid Alzheimer's disease biomarkers in older patients: Evidence from a national multicenter prospective study Open
CSF AD biomarkers added substantial value to clinical assessment in patients over 80. Their use seems crucial in the diagnostic process for older adults referred to memory clinics.
Comparative performance of plasma pTau181/Aβ42, pTau217/Aβ42 ratios, and individual measurements in detecting brain amyloidosis Open
Background Early detection of brain amyloidosis (Aβ+) is crucial for diagnosing Alzheimer’disease (AD) and optimizing patient management, especially in light of emerging treatments. While plasma biomarkers are promising, their combined dia…
P‐tau217 significance as marker of brain Abeta and tau pathologies Open
Background P‐tau217 has emerged as a compelling alternative to long‐established p‐tau181 to accurately measure tau modifications in biofluids in response to brain Abeta and tau deposition in Alzheimer’s disease (AD). Understanding the spec…
Clarifying the association of CSF Aβ, tau, BACE1, and neurogranin with AT(N) stages in Alzheimer disease Open
Background Current AT(N) stratification for Alzheimer’s disease (AD) accounts for complex combinations of amyloid (A), tau proteinopathy (T) and neurodegeneration (N) signatures. Understanding the transition between these different stages …
View article: Association of caffeine consumption with cerebrospinal fluid biomarkers in mild cognitive impairment and Alzheimer's disease: A BALTAZAR cohort study
Association of caffeine consumption with cerebrospinal fluid biomarkers in mild cognitive impairment and Alzheimer's disease: A BALTAZAR cohort study Open
INTRODUCTION We investigated the link between habitual caffeine intake with memory impairments and cerebrospinal fluid (CSF) biomarkers in mild cognitive impairment (MCI) and Alzheimer's disease (AD) patients. METHODS MCI ( N = 147) and AD…
Enabling Population Protein Dynamics Through Bayesian Modeling Open
Motivation The knowledge of protein dynamics, or turnover, in patients provides invaluable information related to certain diseases, drug efficacy, or biological processes. A great corpus of experimental and computational methods has been d…
Modeling the Simultaneous Dynamics of Proteins in Blood Plasma and the Cerebrospinal Fluid in Human <i>In Vivo</i> Open
The analysis of protein dynamics or turnover in patients has the potential to reveal altered protein recycling, such as in Alzheimer's disease, and to provide informative data regarding drug efficacy or certain biological processes. The ob…
Clinical value of plasma ALZpath pTau217 immunoassay for assessing mild cognitive impairment Open
Background Among plasma biomarkers for Alzheimer’s disease (AD), pTau181 and pTau217 are the most promising. However, transition from research to routine clinical use will require confirmation of clinical performance in prospective cohorts…
View article: Association of caffeine consumption with memory deficits and cerebrospinal fluid biomarkers in Mild Cognitive Impairment and Alzheimer’s Disease: a BALTAZAR cohort study
Association of caffeine consumption with memory deficits and cerebrospinal fluid biomarkers in Mild Cognitive Impairment and Alzheimer’s Disease: a BALTAZAR cohort study Open
STRUCTURED ABSTRACT INTRODUCTION We investigated the link between habitual caffeine intake with memory deficits and CSF AD biomarkers in Mild cognitive impairment (MCI) and Alzheimer’s Disease (AD) patients. METHODS MCI (N=147) and AD (N=1…
View article: Intuition Brain Health Study: a smartphone- and smartwatch-based virtual, observational study using multimodal mobile sensing to classify and detect mild cognitive impairment
Intuition Brain Health Study: a smartphone- and smartwatch-based virtual, observational study using multimodal mobile sensing to classify and detect mild cognitive impairment Open
Smart devices are utilized by billions worldwide. The ubiquity of consumer-grade smart devices provides opportunities to robustly capture real-world cognition. Intuition (NCT05058950) was a virtual, observational study that enrolled 23,004…
Clinical value of plasma ALZpath pTau217 immunoassay for assessing mild cognitive impairment Open
Objectives We sought to compare two of the most promising plasma biomarkers for Alzheimer disease (AD): pTau181 and pTau217. Methods pTau181 and pTau217 were quantified using, Quanterix and ALZpath, SIMOA assays in the well characterized p…
Modeling the simultaneous dynamics of proteins in blood plasma and the cerebrospinal fluid in human <i>in vivo</i> Open
The analysis of protein dynamics or turnover in patients has the potential to reveal altered protein recycling such as in Alzheimer disease, and to provide informative data regarding drug efficacy, or certain biological processes. The obse…
Blood Neurofilament Levels Predict Cognitive Decline across the Alzheimer’s Disease Continuum Open
Neurofilament light chain (NfL) is a potential diagnostic and prognostic plasma biomarker for numerous neurological diseases including Alzheimer’s disease (AD). In this study, we investigated the relationship between baseline plasma concen…
The association between Aβ aggregation and age depends on APOE genotype: Findings from the AMYPAD cohort Open
Background The present study aimed to explore the association between Apolipoprotein E (APOE) genotype, the main genetic risk factor for sporadic Alzheimer’s Disease (AD), age, and cerebral β‐amyloid (Aβ) aggregation, the earliest patholog…
View article: Dementia risk‐stratification in a large, decentralized cohort of aging individuals with subjective cognitive complaints from the INTUITION brain health study
Dementia risk‐stratification in a large, decentralized cohort of aging individuals with subjective cognitive complaints from the INTUITION brain health study Open
Background Subjective cognitive complaints (SCC) signal risk of objective cognitive decline. To better understand the bio‐behavioral factors that signal cognitive trajectories at‐risk for the earliest stages of Alzheimer’ disease, there is…
Enabling population protein dynamics through Bayesian modeling Open
The knowledge of protein dynamics or turnover in patients provides invaluable information related to certain diseases, drug efficacy, or biological processes. A great corpus of experimental and computational methods has been developed, inc…
Precision medicine analysis of heterogeneity in individual‐level treatment response to amyloid beta removal in early Alzheimer's disease Open
INTRODUCTION Alzheimer's disease (AD) is a neurological disorder with variability in pathology and clinical progression. AD patients may differ in individual‐level benefit from amyloid beta removal therapy. METHODS Random forest models wer…